If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 1 - 10 of 32
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion
Objective
A Phase 1/2 Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion
Protocol No
MIRATI-1719-001
Categories
Cancer,
Other Skin,
Thoracic Cancers,
Gynecologic Cancers,
Other Gastrointestinal,
Early Phase/Multiple Disease Site Cancers,
Lip, Oral Cavity and Pharynx,
Melanoma, Skin,
Esophagus,
Bladder,
Pancreas/Liver,
Prostate,
Skin Cancers,
Kidney,
Prostate and Urologic Cancers,
Head and Neck Cancers,
Colorectal,
Gastrointestinal Cancers,
Sarcoma,
Breast Cancers
An Open-Label, Navigational Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy for Patients with Aggressive Malignancies and Poor Prognoses
Objective
IIT-GEORGE-I-PREDICT
Protocol No
IIT-GEORGE-I-PREDICT
Categories
Cancer,
Colorectal,
Gynecologic Cancers,
Esophagus,
Other Urologic,
Head and Neck Cancers,
Early Phase/Multiple Disease Site Cancers,
Esophagus,
Skin Cancers,
Stomach,
Prostate and Urologic Cancers,
Pancreas/Liver,
Breast Cancers,
Other Gastrointestinal,
Sarcoma,
Gastrointestinal Cancers,
Lung,
Thoracic Cancers
Adaptive Modification of Neoadjuvant Therapy Based on Clinical Response in Patients with Localized Pancreatic Cancer
Objective
Adaptive Modification of Neoadjuvant Therapy Based on Clinical Response in Patients With Localized Pancreatic Cancer
Protocol No
IIT-TSAI-PANC
Categories
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC)
Objective
Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)
Protocol No
ABK-CA-PROT-85
Categories
A First-in-Human, Multicenter, Phase 1, Open-Label Study of XTX301 in Patients with Advanced Solid Tumors
Objective
A First-in-Human, Open-Label Study of XTX301 in Patients with Advanced Solid Tumors
Protocol No
XILIO-XTX301-01-02-001
Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer with High-Risk of Cancer Recurrence (PROTECT-PANC)
Objective
Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence (PROTECT-PANC)
Protocol No
IIT-KAMGAR-PROTECT-PANC
Categories
PROmoting CLinicAl TrIal EngageMent for Pancreatic Cancer App Study (PROCLAIM Study)
Objective
Promoting CT Engagement for Pancreatic Cancer With App (PROCLAIM)
Protocol No
UNC-LCCC2234-PROCLAIM
Categories
An Open-Label, Multicenter Study of LY4050784, a Selective SMARCA2/BRM Inhibitor, in Advanced Solid Tumor Malignancies with SMARCA4/BRG1 Alterations
Objective
An Open-label, Multicenter Study of LY4050784 in Advanced Solid Tumor Malignancies with SMARCA4/BRG1 Alterations
Protocol No
LOXO-J5M-OX-JOXA
Categories
Cancer,
Stomach,
Prostate,
Breast Cancers,
Other Skin,
Lip, Oral Cavity and Pharynx,
Larynx,
Ovary,
Head and Neck Cancers,
Thoracic Cancers,
Sarcoma,
Other Urologic,
Pancreas/Liver,
Cervix,
Gynecologic Cancers,
Esophagus,
Melanoma, Skin,
Bladder,
Gastrointestinal Cancers,
Prostate and Urologic Cancers,
Early Phase/Multiple Disease Site Cancers,
Skin Cancers
A Phase 2 Study with Combination Chemotherapy (Gemcitabine and Nab-Paclitaxel), Chemokine (C-X-C) Motif Receptor 4 Inhibitor (BL-8040), and Immune Checkpoint Blockade (Cemiplimab) in Metastatic Treatment Naïve Pancreas Adenocarcinoma
Objective
Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma
Protocol No
COLUMBIA-S9513-CHEMO4METPANC
Categories
A Phase I/II Study of VLS-1488 (an Oral KIF18A Inhibitor) in Subjects with Advanced Cancer
Objective
A phase I/II study of VLS-1488 (an oral KIF18A inhibitor) in subjects with advanced cancer
Protocol No
VOLASTRA-VLS-1488-2201